行情

AGRX

AGRX

Agile
NASDAQ

实时行情|Nasdaq Last Sale

1.690
-0.050
-2.88%
交易中 14:44 11/22 EST
开盘
1.760
昨收
1.740
最高
1.770
最低
1.660
成交量
103.14万
成交额
--
52周最高
2.970
52周最低
0.3500
市值
1.00亿
市盈率(TTM)
-4.2438
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AGRX 新闻

  • Daily Insider Ratings Round Up 11/18/19
  • Seeking Alpha - Article.1天前
  • I, BCRX, AGRX and THMO among midday movers
  • Seeking Alpha - Article.3天前
  • Agile: FDA Decision To Extend Twirla's PDUFA Date Provides Buying Opportunity
  • Seeking Alpha - Article.4天前
  • Microcaps mostly among midday movers
  • Seeking Alpha - Article.11/15 17:58

更多

所属板块

生物技术和医学研究
+1.63%
制药与医学研究
+0.76%

热门股票

名称
价格
涨跌幅

AGRX 简况

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
展开

Webull提供Agile Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。